Intellia Therapeutics (NASDAQ: NTLA) has been getting a lot of buzz lately among investors who follow the biotech space.
The company uses CRISPR gene editing technology to develop treatments, and while their stock has been all over the place historically, something’s changed in 2025 that has people taking notice.
Analysts and big institutional investors have been piling into the stock recently, which usually means they’re seeing something promising in the company’s pipeline or business prospects.
Cathie Wood’s ARK Invest ETFs became the latest player to invest around $4 million for 349,930 Intellia shares.
Renewed market optimism despite stock price volatility
Intellia’s stock has had a rough stretch over the past year, dropping from above $30 to about $11.36 by late August 2025.
The near-term picture doesn’t look much better, with some expecting another 10% slide in September.
Even so, analysts are still positive on the longer-term story, pointing more to Intellia’s research progress and drug pipeline than to short-term trading swings.
Recently, Intellia has been getting more attention. Partnerships, some movement on the regulatory side, and updates from trials have all helped build a little more confidence that the company isn’t going anywhere.
A few hedge funds and big investors have even been picking up more shares, looking at Intellia as one of the better bets in gene editing, with CRISPR treatments inching toward approval.
The stock itself is still pretty shaky, but a couple of technical signals, things like trading volume and relative strength, suggest it might be starting to level out.
If that holds, it could set the stage for a rebound. Some people see it moving back into the $13–$15 range by early 2026, but that really depends on how the next wave of trial results and commercial updates turn out.
Pipeline potential drives analyst interest
What really has analysts excited is Intellia’s push into gene editing for rare diseases using CRISPR.
Its leading projects, most notably the in vivo therapy for transthyretin amyloidosis (ATTR) and a handful of other single-gene conditions, have turned up encouraging early data.
That progress is giving Intellia a bit of separation from the pack of other companies working in the same space.
On the financial side, Intellia faces the usual hurdles for a biotech still in the clinic, heavy spending on research and development, while running at a loss.
Its market value is about $1.2 billion, but revenue remains slim since it’s still early in commercialization.
That makes fresh funding a necessity, and it’s one reason bigger investors have been building positions ahead of what they see as the company’s next growth phase.
The post Why big players are pouring millions in THIS biotech stock appeared first on Invezz